Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caloxetic Acid Free Base SCHEMBL8412091 | 1.00 | MAOB (0.43) | MAOBALOX5ACACBALDH1A1POLB | |
| Caloxetic Acid Free Base SCHEMBL19667948 | 0.99 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| Caloxetic Acid Free Base SCHEMBL29375456 | 0.99 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| Caloxetic Acid Free Base SCHEMBL19667947 | 0.99 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21919169 | 0.95 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21327618 | 0.94 | MAOB (0.41) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21919234 | 0.94 | MAOB (0.41) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL21327620 | 0.94 | MAOB (0.41) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL8672662 | 0.94 | MAOB (0.42) | MAOBALOX5ACACBALDH1A1POLB | |
| SCHEMBL8341415 | 0.94 | MAOB (0.46) | MAOBALOX5ACACBALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464237-B1 | NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM) | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2023-12-20 | — | — | EP | claimed |
| WO-2023076220-A1 | CONJUGATES HAVING ANTIFOULING NANOPARTICLES AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-04 | — | — | WO | claimed |
| US-11110185-B2 | Combination formulation | GE HEALTHCARE AS (NO) | 2021-09-07 | — | — | US | claimed |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2020-04-23 | — | — | US | claimed |
| US-20180303960-A1 | Combination Formulation | GE HEALTHCARE AS (NO) | 2018-10-25 | — | — | US | claimed |
| EP-3383441-A1 | FORMULATIONS COMPRISING A COMBINATION OF MRI CONTRAST AGENTS | GE Healthcare AS (NO) | 2018-10-10 | — | — | EP | claimed |
| WO-2017093336-A1 | FORMULATIONS COMPRISING A COMBINATION OF MRI CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2017-06-08 | — | — | WO | claimed |
| EP-2547369-B1 | A NANOPARTICLE COMPRISING A MICELLE FORMED BY AN AMPHIPHILIC BLOCK-COPOLYMER AND ENCAPSULATING A GADOLINIUM COMPLEX | UNIV KING SAUD (SA) | 2017-04-19 | — | — | EP | claimed |
| US-20140234211-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | INVECTORS S.R.L. (IT) | 2014-08-21 | — | — | US | claimed |
| EP-2750714-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | INVECTORS s.r.l. (IT) | 2014-07-09 | — | — | EP | claimed |
| EP-1412383-A2 | PEPTIDES CONJUGATES, THEIR DERIVATIVES WITH METAL COMPLEXES AND USE THEREOF FOR MAGNETIC RESONANCE IMAGING (MRI) | Bracco Imaging S.p.A. (IT) | 2004-04-28 | — | — | EP | claimed |
| WO-2003103722-A1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING S.P.A. (IT) | 2003-12-18 | — | — | WO | claimed |
| EP-1369134-A1 | New agents for magnetic imaging method | Bracco Imaging S.p.A. (IT) | 2003-12-10 | — | — | EP | claimed |
| WO-2003014157-A2 | PEPTIDES CONJUGATES, THEIR DERIVATIVES WITH METAL COMPLEXES AND USE THEREOF FOR MAGNETIC RESONANCE IMAGING (MRI) | BRACCO IMAGING S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| EP-0743283-B1 | Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes | BRACCO IMAGING SPA (IT) | 2001-06-27 | — | — | EP | claimed |
| US-6039931-A | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-21 | — | — | US | claimed |
| US-5695739-A | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | claimed |
| US-5595714-A | Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes | DIBRA S.P.A. (IT) | 1997-01-21 | — | — | US | claimed |
| EP-0743283-A2 | Recovery of gadolinium and its complexing agents from aqueous solutions containing their complexes | BRACCO S.p.A. (IT) | 1996-11-20 | — | — | EP | claimed |
| EP-0405704-B1 | DTPA-complexes derivatives, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AG (DE) | 1994-12-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110185-B2 | Combination formulation | SLC10A1, SLC10A2, RXFP2 | MAOB 590/4885ALOX5 2056/4885ACACB 2732/4885 |
| US-20140234211-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | GRPR, BRS3, BID | MAOB 4319/4885ALOX5 3753/4885ACACB 4701/4885 |
| US-20200123178-A1 | Novel Process for the Preparation of Gadolinium Complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-Tris(Carboxylatomethyl)-3,6,9-Triazaundecanedioic Acid Disodium (Gadoxetate Disodium) | GLRX3, CA9, CA4 | MAOB 1325/4885ALOX5 2520/4885ACACB 3088/4885 |
| US-20180303960-A1 | Combination Formulation | SLC10A1, SLC10A2, RXFP2 | MAOB 590/4885ALOX5 2056/4885ACACB 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.